The role of clopidogrel in the emergency department

Canadian Journal of Emergency Medicine

Volumn 7, Issue 1, 2005, Pages 22-27

  Patel, Payal ^a   Cheng, Lily ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b FRASER HEALTH AUTHORITY   (Canada)

Author keywords

ACS; Acute coronary syndromes; Clopidogrel

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; EPTIFIBATIDE; TICLOPIDINE; TIROFIBAN;

BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; NEUTROPENIA; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 28044458543     PISSN: 14818035     EISSN: 14818035     Source Type: Journal    
DOI: 10.1017/S1481803500012896     Document Type: Review

References (27)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. Available: www.acc.org/clinical/guidelines/unstable/unstable.pdf (accessed 2004 Dec 15).
2. Heart and Stroke Foundation of Canada with the Centre for Chronic Disease Prevention and Control, Health Canada, Canadian Cardiovascular Society. The growing burden of heart disease and stroke in Canada 2003. Available: www.cvdinfobase.ca/cvdbook/CVD_En03.pdf (accessed 2004 Nov 16).
3. White HD. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol 1997;80(suppl 4A):2B-10B.
4. Mathis AS. Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes. Ann Pharmacother 2000;34:208-27.
5. Kullo IJ, Edwards WD, Shwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 1998;129:1050-60.
6. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97:1195-206.
7. Ferguson JJ. Conventional antithrombotic approaches. Am Heart J 1995;130:651-7.
8. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intra-coronary stent implantation in a broad patient population. Circulation 2001;104:539-43.
9. Bertrand ME, Rupprescht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102:624-9.
10. Yusuf S, Zhao F, Mehta SR, Chrolavisius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published errata appear in N Engl J Med 2001;345(20):1506 and N Engl J Med 2001;345 (23):1716]. N Engl J Med 2001;345(7):494-502.
11. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovas Drug Rev 1993;2:180-98.
12. Mills DCB, Puri R, Hu CJ, Minnily C, Grana G, Freedman MD, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992;2:430-6.
13. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999;25(suppl 2):25-8.
14. Savcic M, Hauert J, Backmann F, Wyld P, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(suppl 2):15-9.
15. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003;107:32-7.
16. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8.
17. Sharis P, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405.
18. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
19. Berger PB, Bell MR, Rihal CS, Ting H, Barsness G, Garatt K, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34:1891-4.
20. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364-6.
21. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590-3.
22. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
23. Mehta SR, Yusuf S, Peters PJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
24. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-15.
25. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
26. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention [published erratum appears in JAMA 2003;289(8):987]. JAMA 2002;288(19):2411-20.
27. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. J Intern Med 2004;255:562-7.